Logo image of CNTB

CONNECT BIOPHARMA HOLDINGS L (CNTB) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CNTB - KYG235491019 - Common Stock

2.81 USD
-0.02 (-0.71%)
Last: 11/28/2025, 8:21:11 PM
2.77 USD
-0.04 (-1.42%)
After Hours: 11/28/2025, 8:21:11 PM
Fundamental Rating

3

Taking everything into account, CNTB scores 3 out of 10 in our fundamental rating. CNTB was compared to 533 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CNTB as it has an excellent financial health rating, but there are worries on the profitability. CNTB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year CNTB has reported negative net income.
In the past year CNTB has reported a negative cash flow from operations.
CNTB had negative earnings in each of the past 5 years.
CNTB had a negative operating cash flow in each of the past 5 years.
CNTB Yearly Net Income VS EBIT VS OCF VS FCFCNTB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M -800M -1B

1.2 Ratios

Looking at the Return On Assets, with a value of -7.88%, CNTB belongs to the top of the industry, outperforming 85.74% of the companies in the same industry.
Looking at the Return On Equity, with a value of -8.66%, CNTB belongs to the top of the industry, outperforming 88.74% of the companies in the same industry.
Industry RankSector Rank
ROA -7.88%
ROE -8.66%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CNTB Yearly ROA, ROE, ROICCNTB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 50 -50

1.3 Margins

CNTB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CNTB Yearly Profit, Operating, Gross MarginsCNTB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

More info and screens

8

2. Health

2.1 Basic Checks

CNTB does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for CNTB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CNTB Yearly Shares OutstandingCNTB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
CNTB Yearly Total Debt VS Total AssetsCNTB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B

2.2 Solvency

CNTB has an Altman-Z score of 6.76. This indicates that CNTB is financially healthy and has little risk of bankruptcy at the moment.
CNTB has a Altman-Z score of 6.76. This is in the better half of the industry: CNTB outperforms 77.49% of its industry peers.
CNTB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.76
ROIC/WACCN/A
WACC8.65%
CNTB Yearly LT Debt VS Equity VS FCFCNTB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 1B -1B 2B

2.3 Liquidity

A Current Ratio of 11.46 indicates that CNTB has no problem at all paying its short term obligations.
CNTB's Current ratio of 11.46 is amongst the best of the industry. CNTB outperforms 85.93% of its industry peers.
A Quick Ratio of 11.46 indicates that CNTB has no problem at all paying its short term obligations.
CNTB's Quick ratio of 11.46 is amongst the best of the industry. CNTB outperforms 85.93% of its industry peers.
Industry RankSector Rank
Current Ratio 11.46
Quick Ratio 11.46
CNTB Yearly Current Assets VS Current LiabilitesCNTB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

More info and screens

2

3. Growth

3.1 Past

CNTB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 47.93%, which is quite impressive.
Looking at the last year, CNTB shows a quite strong growth in Revenue. The Revenue has grown by 8.15% in the last year.
EPS 1Y (TTM)47.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-268.77%
Revenue 1Y (TTM)8.15%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-99.8%

3.2 Future

The Earnings Per Share is expected to grow by 10.88% on average over the next years. This is quite good.
The Revenue is expected to decrease by -18.26% on average over the next years. This is quite bad
EPS Next Y-205.4%
EPS Next 2Y-56.18%
EPS Next 3Y-25.82%
EPS Next 5Y10.88%
Revenue Next Year-99.99%
Revenue Next 2Y-35.23%
Revenue Next 3Y-10.22%
Revenue Next 5Y-18.26%

3.3 Evolution

CNTB Yearly Revenue VS EstimatesCNTB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
CNTB Yearly EPS VS EstimatesCNTB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10 -15 -20 -25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CNTB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CNTB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CNTB Price Earnings VS Forward Price EarningsCNTB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CNTB Per share dataCNTB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

CNTB's earnings are expected to decrease with -25.82% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-56.18%
EPS Next 3Y-25.82%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CNTB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CONNECT BIOPHARMA HOLDINGS L

NASDAQ:CNTB (11/28/2025, 8:21:11 PM)

After market: 2.77 -0.04 (-1.42%)

2.81

-0.02 (-0.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)N/A N/A
Inst Owners44.24%
Inst Owner Change-32.56%
Ins Owners0.7%
Ins Owner ChangeN/A
Market Cap156.58M
Revenue(TTM)26.08M
Net Income(TTM)-7.98M
Analysts84.44
Price Target7.78 (176.87%)
Short Float %0.2%
Short Ratio0.45
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)11.59%
PT rev (3m)11.59%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)24.7%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.12
P/FCF N/A
P/OCF N/A
P/B 1.7
P/tB 1.7
EV/EBITDA N/A
EPS(TTM)-0.51
EYN/A
EPS(NY)-3.84
Fwd EYN/A
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS0.9
BVpS1.65
TBVpS1.65
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7.88%
ROE -8.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 113.64%
Cap/Sales 1.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.46
Quick Ratio 11.46
Altman-Z 6.76
F-Score5
WACC8.65%
ROIC/WACCN/A
Cap/Depr(3y)182.41%
Cap/Depr(5y)444.25%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-268.77%
EPS Next Y-205.4%
EPS Next 2Y-56.18%
EPS Next 3Y-25.82%
EPS Next 5Y10.88%
Revenue 1Y (TTM)8.15%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-99.8%
Revenue Next Year-99.99%
Revenue Next 2Y-35.23%
Revenue Next 3Y-10.22%
Revenue Next 5Y-18.26%
EBIT growth 1Y88.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y49.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.54%
OCF growth 3YN/A
OCF growth 5YN/A

CONNECT BIOPHARMA HOLDINGS L / CNTB FAQ

Can you provide the ChartMill fundamental rating for CONNECT BIOPHARMA HOLDINGS L?

ChartMill assigns a fundamental rating of 3 / 10 to CNTB.


What is the valuation status of CONNECT BIOPHARMA HOLDINGS L (CNTB) stock?

ChartMill assigns a valuation rating of 0 / 10 to CONNECT BIOPHARMA HOLDINGS L (CNTB). This can be considered as Overvalued.


What is the profitability of CNTB stock?

CONNECT BIOPHARMA HOLDINGS L (CNTB) has a profitability rating of 2 / 10.


How financially healthy is CONNECT BIOPHARMA HOLDINGS L?

The financial health rating of CONNECT BIOPHARMA HOLDINGS L (CNTB) is 8 / 10.